Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus

Sung Soo Ahn, Seung Min Jung, Juyoung Yoo, Sang Won Lee, Jason Jungsik Song, Yong Beom Park

Research output: Contribution to journalArticle

Abstract

Although anti-Smith (Sm) antibody is a highly specific antibody for systemic lupus erythematosus (SLE), the significance of anti-Sm antibody in patients with SLE is unclear. This study aimed to evaluate the association between anti-Sm antibodies and disease activity in patients with new-onset SLE. We included patients who were tested for anti-Sm antibodies at SLE diagnosis and within 12 months after diagnosis. SLE disease activity index (SLEDAI) was obtained at the time of the anti-Sm antibody test. The baseline disease activity was compared between patients with and without anti-Sm antibodies. The longitudinal association between disease activity and anti-Sm antibodies was also evaluated in total patients and in those with anti-Sm antibodies. Among 92 patients who were tested for anti-Sm antibodies at SLE diagnosis, 67 and another 67 patients were followed up for the presence of anti-Sm antibodies at 6 and 12 months, respectively. Although the baseline SLEDAI was comparable in patients with and without anti-Sm antibodies, the serum level of anti-Sm antibody was significantly correlated with SLEDAI (P = 0.003). At 12 months, anti-Sm antibody positivity was associated with higher SLEDAI and anti-dsDNA titer (P = 0.002, both). In addition, the changes in anti-Sm antibody titer over 12 months were correlated with the alterations in SLEDAI (P = 0.029).Anti-Sm antibody was associated with the baseline disease activity and the alteration of disease activity in patients with new-onset SLE. Monitoring of anti-Sm antibody titer may help assess the disease activity in SLE.

Original languageEnglish
Pages (from-to)1937-1944
Number of pages8
JournalRheumatology International
Volume39
Issue number11
DOIs
Publication statusPublished - 2019 Nov 1

Fingerprint

Systemic Lupus Erythematosus
Anti-Idiotypic Antibodies

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Ahn, Sung Soo ; Jung, Seung Min ; Yoo, Juyoung ; Lee, Sang Won ; Song, Jason Jungsik ; Park, Yong Beom. / Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus. In: Rheumatology International. 2019 ; Vol. 39, No. 11. pp. 1937-1944.
@article{53831112fb6d49de802f7a8a62e4900d,
title = "Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus",
abstract = "Although anti-Smith (Sm) antibody is a highly specific antibody for systemic lupus erythematosus (SLE), the significance of anti-Sm antibody in patients with SLE is unclear. This study aimed to evaluate the association between anti-Sm antibodies and disease activity in patients with new-onset SLE. We included patients who were tested for anti-Sm antibodies at SLE diagnosis and within 12 months after diagnosis. SLE disease activity index (SLEDAI) was obtained at the time of the anti-Sm antibody test. The baseline disease activity was compared between patients with and without anti-Sm antibodies. The longitudinal association between disease activity and anti-Sm antibodies was also evaluated in total patients and in those with anti-Sm antibodies. Among 92 patients who were tested for anti-Sm antibodies at SLE diagnosis, 67 and another 67 patients were followed up for the presence of anti-Sm antibodies at 6 and 12 months, respectively. Although the baseline SLEDAI was comparable in patients with and without anti-Sm antibodies, the serum level of anti-Sm antibody was significantly correlated with SLEDAI (P = 0.003). At 12 months, anti-Sm antibody positivity was associated with higher SLEDAI and anti-dsDNA titer (P = 0.002, both). In addition, the changes in anti-Sm antibody titer over 12 months were correlated with the alterations in SLEDAI (P = 0.029).Anti-Sm antibody was associated with the baseline disease activity and the alteration of disease activity in patients with new-onset SLE. Monitoring of anti-Sm antibody titer may help assess the disease activity in SLE.",
author = "Ahn, {Sung Soo} and Jung, {Seung Min} and Juyoung Yoo and Lee, {Sang Won} and Song, {Jason Jungsik} and Park, {Yong Beom}",
year = "2019",
month = "11",
day = "1",
doi = "10.1007/s00296-019-04445-y",
language = "English",
volume = "39",
pages = "1937--1944",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "11",

}

Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus. / Ahn, Sung Soo; Jung, Seung Min; Yoo, Juyoung; Lee, Sang Won; Song, Jason Jungsik; Park, Yong Beom.

In: Rheumatology International, Vol. 39, No. 11, 01.11.2019, p. 1937-1944.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus

AU - Ahn, Sung Soo

AU - Jung, Seung Min

AU - Yoo, Juyoung

AU - Lee, Sang Won

AU - Song, Jason Jungsik

AU - Park, Yong Beom

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Although anti-Smith (Sm) antibody is a highly specific antibody for systemic lupus erythematosus (SLE), the significance of anti-Sm antibody in patients with SLE is unclear. This study aimed to evaluate the association between anti-Sm antibodies and disease activity in patients with new-onset SLE. We included patients who were tested for anti-Sm antibodies at SLE diagnosis and within 12 months after diagnosis. SLE disease activity index (SLEDAI) was obtained at the time of the anti-Sm antibody test. The baseline disease activity was compared between patients with and without anti-Sm antibodies. The longitudinal association between disease activity and anti-Sm antibodies was also evaluated in total patients and in those with anti-Sm antibodies. Among 92 patients who were tested for anti-Sm antibodies at SLE diagnosis, 67 and another 67 patients were followed up for the presence of anti-Sm antibodies at 6 and 12 months, respectively. Although the baseline SLEDAI was comparable in patients with and without anti-Sm antibodies, the serum level of anti-Sm antibody was significantly correlated with SLEDAI (P = 0.003). At 12 months, anti-Sm antibody positivity was associated with higher SLEDAI and anti-dsDNA titer (P = 0.002, both). In addition, the changes in anti-Sm antibody titer over 12 months were correlated with the alterations in SLEDAI (P = 0.029).Anti-Sm antibody was associated with the baseline disease activity and the alteration of disease activity in patients with new-onset SLE. Monitoring of anti-Sm antibody titer may help assess the disease activity in SLE.

AB - Although anti-Smith (Sm) antibody is a highly specific antibody for systemic lupus erythematosus (SLE), the significance of anti-Sm antibody in patients with SLE is unclear. This study aimed to evaluate the association between anti-Sm antibodies and disease activity in patients with new-onset SLE. We included patients who were tested for anti-Sm antibodies at SLE diagnosis and within 12 months after diagnosis. SLE disease activity index (SLEDAI) was obtained at the time of the anti-Sm antibody test. The baseline disease activity was compared between patients with and without anti-Sm antibodies. The longitudinal association between disease activity and anti-Sm antibodies was also evaluated in total patients and in those with anti-Sm antibodies. Among 92 patients who were tested for anti-Sm antibodies at SLE diagnosis, 67 and another 67 patients were followed up for the presence of anti-Sm antibodies at 6 and 12 months, respectively. Although the baseline SLEDAI was comparable in patients with and without anti-Sm antibodies, the serum level of anti-Sm antibody was significantly correlated with SLEDAI (P = 0.003). At 12 months, anti-Sm antibody positivity was associated with higher SLEDAI and anti-dsDNA titer (P = 0.002, both). In addition, the changes in anti-Sm antibody titer over 12 months were correlated with the alterations in SLEDAI (P = 0.029).Anti-Sm antibody was associated with the baseline disease activity and the alteration of disease activity in patients with new-onset SLE. Monitoring of anti-Sm antibody titer may help assess the disease activity in SLE.

UR - http://www.scopus.com/inward/record.url?scp=85073522278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073522278&partnerID=8YFLogxK

U2 - 10.1007/s00296-019-04445-y

DO - 10.1007/s00296-019-04445-y

M3 - Article

C2 - 31552434

AN - SCOPUS:85073522278

VL - 39

SP - 1937

EP - 1944

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 11

ER -